For early-stage, HR+ Her2- breast cancers, when do you use OncotypeDx v. Mammaprint?  

The reason to use any multiparameter assay is to determine which patients needs chemo and which don't. To say that another way -it is about the predictive ability,not the prognostic ability. Until very recently Mammaprint only had prognostic data so I always used Oncotype. The MINDACT trial recently...

@Kathy Miller, I heard a talk where the speaker, based on MIndAct trial data used Mammaprint for early stage node positive patients to select patients that WILL NOT benefit from chemo (sparing chemo for almost half of those women). Conversely he used OncotypeDx for early stage node negative breast c...